- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18:46 | Pfizer shelves haemophilia gene therapy Beqvez amid low demand | ||
| 17:46 | UroGen acquires IconOVir's oncolytic virus assets | ||
| 15:46 | GLP-1 receptor agonists could hold promise for opioid use disorder treatment | ||
| 14:46 | How CNS researchers are handling clinical trial turbulence | ||
| 14:46 | NICE green lights two blood cancer therapies for NHS use | ||
| 14:46 | Incyte and Genesis collaborate on small-molecule medicines | ||
| 12:46 | Navigating the Complexities of Sustainable Specialty Pharma Supply Chains | ||
| 11:46 | Japan's MHLW approves CSL Behring's Andembry to stop HAE attacks | ||
| Do | Zealand Pharma steadfastly upholds amylin-based obesity drug strategy | ||
| Do | X4 and taiba to distribute WHIM syndrome therapy in Middle East | ||
| Do | Key pharma launch trends in 2024 | ||
| Do | WHO targets over half a million children in Gaza for polio vaccine drive | ||
| Do | FDA authorises ImmunityBio's BCG alternative to treat bladder cancer | ||
| Do | Pharma and medtech industry reacts to FDA, CDC and NIH job cuts | ||
| Do | FDA grants priority review for Boehringer's zongertinib NDA in NSCLC | ||
| Mi | Scientists develop largest ever biological AI model that 'thinks in nucleotides' | ||
| Mi | Supernus's stock sinks after depression drug fails trial | ||
| Mi | Sanofi moves closer to selling controlling stake in $17bn-valued Opella | ||
| Mi | Cumberland's Vibativ injection gains China's NMPA approval | ||
| Mi | Amazon joins forces with Memorial Sloan Kettering for AI-powered drug discovery | ||
| Mi | GLP-1RAs and opioid use disorder: a new frontier in addiction treatment | ||
| Mi | Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment | ||
| Mi | Can innovation in clinical trial delivery meet the demands of increasing complexity in drug development? | ||
| Mi | New CEOs to join Merck KGaA's executive board | ||
| Di | Gilead's lenacapavir moves closer to FDA approval for HIV PrEP use |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
